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Purpose 
To examine the cross-sectional association between anti-cholinergic medication burden (ACB) 
and a history of falls, bone mineral density (BMD), and low trauma fractures in middle-aged 
women under 65 years of age from the Aberdeen Prospective Osteoporosis Screening Study 
(APOSS). 
Methods 
ACB (0= none, 1=possible, ≥2= definite) was calculated from medication use for 3883 
Caucasian women (mean age (SD) = 54.3 (2.3) years) attending the second APOSS study visit 
(1997-2000). Outcomes were examined using logistic regression. Model adjustments were 
selected a-priori based on expert opinion.  
Results 
Of 3883 participants, 3293 scored ACB  = 0, 328 scored ACB = 1, and 262 scored ACB > 2. 
High ACB burden (≥2) was associated with increased odds (ACB=0 reference) for falls (fully 
adjusted OR (95% CI) = 1.81 (1.25-2.62); P=0.002), and having low BMD (lowest quintile- 
20%) at Ward’s triangle (3.22 (1.30-7.99); P=0.01). A history of falls over the year prior to 
study visits in participants with ACB score ≥2 was 32 per 100. For ACB categories 1 and 0, a 
history of falls per 100 was 21 and 22 respectively.  
Conclusions 
The risk of falling associated with ACB observed in older age may also extend to middle-age 
women.    
 
 
 
Introduction  
Medications with anti-cholinergic properties, used to treat a range of common 
conditions, act by inhibiting the neurotransmitter acetylcholine (ACh), resulting in a relatively 
high side-effect profile [1-3]. Serious adverse effects of anti-cholinergic medications have been 
reported, leading to a reduction in overall quality of life [2-4]. A systematic review of 5 
randomised controlled trials in 6526 participants with a mean age of 78.7 years showed that 
anti-cholinergic medication use was associated with decreased mobility and ability to carry out 
routine daily tasks [1]. In a large community based study of 6343 men and women (mean age 
= 73.7 years) spanning over 4 years, anti-cholinergic medication use was associated with an 
increased risk of falling (adjusted odds ratio = 1.6 (1.2–2.1)) during routine daily activities [5].  
It is estimated that one in two Caucasian women will suffer a low trauma fracture during 
their life time. Poor physical function and falling are important risk factors for low trauma 
fracture [6]. In a meta-analysis of 19 RCTs containing 1577 participants (mean age = 65-83 
years, 85% female), decreased physical activity was found to be associated with a reduction in 
BMD at the lumbar spine and neck of femur (weighted mean difference = 0.011 g/cm2 and 
0.016 g/cm2) [7]. BMD measurement with DXA at the femoral neck is predictive of hip 
fracture, with an increase in risk ratio of 2.88 (95% CI = 2.31-3.59) in women aged 65 years 
for each SD decrease in BMD [8].  
Whether use of medications with anti-cholinergic properties is associated with falls or 
fractures in middle age has not been examined previously. We postulate that such evidence 
would provide incentive to reduce anti-cholinergic burden in early life as this could impact  
healthy ageing. Consequently, the aim of this study was to examine the association between 
anti-cholinergic medication use and a history of falls in the last year, low trauma fractures, and 
BMD at fracture prone sites in a cohort of middle-aged women under the age of 65 years.  
 Methods 
Study participants and design 
Participants were drawn from the Aberdeen Prospective Osteoporosis Screening Study 
(APOSS). Briefly, between 1990 and 1993, 7,200 women aged 45-54 years, living within a 32 
km radius of the Osteoporosis Research Unit in Aberdeen, North East of Scotland, UK with a 
catchment population of approximately 500,000 were selected at random from the Community 
Health Index (a primary care patient register).  These women were invited to take part in a 
screening study for osteoporosis (5, 119 attended), which consisted of a DXA scan of the hip 
and lumbar spine and completion of an osteoporosis risk factor questionnaire [9]. Between 
1997 and 2000, participants who attended the baseline visit were invited for a follow-up visit. 
Three thousand eight hundred and eighty-three women attended. The ACB Score for each 
participant was calculated using a detailed self-reported medication list collected during this 
second visit; prior to the DXA scan, a radiographer asked each participant which medications 
they were currently taking.  
 
Data collection 
Using the Aging Brain Program’s ACB scoring table (as shown in the Supplementary 
Table) [10], each medication was assigned an ACB score and the total ACB burden was 
calculated for each participant as described by Myint et al [11]. There are multiple ant-
cholinergic scoring scales, however, we chose to use the ACB scale because it has previously 
been shown to describe the association between anti-cholinergic medication use and falls in 
older adults [3]. In addition to the established anti-cholinergic medications, we also classed 
Prochlorperazine (or Chlorperazine) and Procyclidine as scoring 3 after consultation with 
opinion leaders in the field. Each participants’ total score was categorised into one of the three 
groups depending on the sum of their total ACB score (ACB = 0, ACB = 1, ACB ≥ 2) (see 
Supplementary Table 1 for the scoring system).  Our rationale for using ACB 2 category as 
opposed to ACB1 category is based upon the wider literature which has shown that ACB ≥2 
is associated with poor outcomes such as mortality [12]. 
 Participants were weighed wearing light clothing and no shoes with scales that were 
calibrated to 0.05kg (Seca, Hamburg, Germany). Height was measured using a stadiometer 
(Holtain Ltd, Crymych, UK). Body Mass Index (BMI) was calculated using the formula (BMI= 
weight (kg)/height (m)2). Physical activity level (PAL) was obtained by questionnaire, which 
asked about usual activities over the previous year [13]. PAL is defined as the ratio of overall 
daily energy expenditure to BMR and was calculated from the number of hours in a 24-h period 
spent doing heavy, moderate, or light activities and the numbers of hours in the same period 
spent sleeping or resting in bed. These questions were asked separately for workdays and non-
work days. Detailed methodology has been previously described [14].  
Information on comorbidities was self-reported and collected at baseline by asking 
about history of osteoporosis, osteoarthritis, rheumatoid arthritis, asthma, kidney disease, 
thyroid disease, diabetes mellitus, hypertension, myocardial infarction, and stroke. Data were 
also collected on the use of the following medications: corticosteroids, calcium supplements, 
osteoporosis medication, anti-epileptic medication, diuretics, sex hormones including the oral 
contraceptive and tamoxifen by asking the question “what prescribed medications have you 
ever taken?”. Participants were asked about smoking status (never, past, or current smoker), 
and family history of low trauma fractures. Vitamin D status was determined by measuring 
serum total 25ODH using high-performance liquid chromatography, which is further described 
by Welsh et al [15].  
Self-reported falls in the past year and prevalent fractures were captured based on 
responses to the questions “Have you fallen in the last 12 months?” and “Have you ever 
fractured a bone?”, respectively. BMD DXA measurements were performed using Norland 
DXA scanners (Cooper Surgical Inc, Trumbull, CT). Scanner calibration was performed daily, 
and quality assurance checks were made by measuring the manufacturer’s phantom at daily 
intervals and a hologic phantom at weekly intervals. The in vivo precision (CV) at our unit of 
the XR26 scanner is 1.95% and 2.31% (lumbar spine and femoral neck respectively). These 
values were determined by duplicate measurements in 8 women aged 49–63 y (mean: 53 y). 
The majority of participants were scanned using an XR26 but 351 women (11.3%) were 
scanned using an XR36. There was a small difference (1.258%) in mean BMD when comparing 
50 phantom measurements on both machines and a correction factor was used to convert the 
XR36 values to XR26-equivalent values.  
 
Statistical Analyses  
All analyses were performed using Statistical Package for Social Science (SPSS), 
version 23.0.  Descriptive statistics of the full cohort and by ACB category were presented. 
ANOVA and chi-square test were used respectively to analyse the association between ACB 
category and measured outcomes. Logistic regression models were constructed to examine the 
association between ACB as the predictor variable (with ACB score of 0 as the reference 
category) and dichotomised outcomes.  BMD data were dichotomised for logistic regression 
analyses; lowest 20% vs. remaining 80%. These arbitrary cut off points allow meaningful 
interpretation of results in terms of the population at risk of detrimental effects from having 
low BMD and to contextualise results for clinicians [16]. For all logistic regression models, 
analyses were unadjusted (model A), adjusted for age, BMI, and HRT use (model B), with 
further incremental adjustment for menopausal status and PAL (model C), comorbidities 
(model D), and use of medications (model E). Multiple linear regression analyses were also 
completed using the same models for our measured BMD sites using continuous BMD values. 
Collected participant demographics and comorbidities were selected according to an adaptation 
of the Functional Comorbidity Index proposed by Groll et al [17].   
 
Results  
The characteristics of the sample by category of total ACB (score 0, score 1, score ≥2) 
are presented in Table 1. Of 3883 participants, 3293 had ACB score 0, 328 had ACB score 1, 
and 262 had ACB score ≥2. The mean age (SD) of study participants was 54.3 (± 2.3) years. 
3496 of our participants were post-menopausal, of which 1418 were taking HRT. Age and BMI 
increased with increasing ACB score, whereas PAL decreased with increasing ACB. There 
was a greater proportion of post-menopausal participants who were currently taking HRT with 
an ACB score of ≥2 compared to pre- and peri-menopausal participants. There were no 
differences in the proportion of participants with self-reported osteoporosis, osteoarthritis, 
thyroid disease, or a family history of fractures across ACB categories. Self-reported 
comorbidity numbers were highest in participants with ACB score of ≥ 2. Use of steroid tablets, 
diuretics, and anti-epileptics, were significantly different across ACB score categories (use of 
corticosteroids and anti-epileptics were highest in participants with ACB score of ≥ 2).   
ACB ≥2 was associated with a history of self-reported falls over the last year in 
univariate (1.71 (1.30-2.25); P = <0.001) and fully adjusted logistic regression models (1.80 
(1.25-2.60); P = 0.002) (Table 2). Per 100 population, a history of falls in the last year for 
participants with ACB score ≥2 was 32. For ACB categories 1 and 0, a history of falls in the 
last year per 100 was 21 and 22 respectively. Both univariate and multiple variable logistic 
regression models showed that ACB score of ≥2 was associated with increased odds for lowest 
quintile BMD (lowest 20%) at Ward’s triangle (OR = 2.81 (1.16-6.79); P = 0.022) for fully 
adjusted model) (Table 3). We found no association between ACB and lowest quintile total 
hip, trochanter, neck of femur, or lumbar spine BMD. There was no association between ACB 
and having ever fractured a bone nor having fractured a bone since turning 50 years of age. 
 
Discussion 
To the best of our knowledge, this is the first study to investigate the association 
between anti-cholinergic burden and musculoskeletal health outcomes in middle-aged women 
under the age of 65. Our study therefore addresses this evidence gap. We found a high ACB 
score from use of anti-cholinergic medications is associated with an increased likelihood of 
having fallen in the last year in this age group. We found no association between ACB and 
BMD except at Ward’s triangle. No association was found between ACB score and having ever 
fractured a bone.  
Falls in older people are a global issue; the average health system cost per one fall injury 
episode for people 65 years and older in Finland and Australia was US$ 3611 and US$ 1049 
[18]. Meanwhile in England, falls cost the NHS £2.3 billion per year and are responsible for 
over 4 million hospital bed days annually [19]. Earlier observational studies examining the 
association between ACB and falls in older adults show conflicting results [3, 5, 20-22]. Zia 
and colleagues observed in a cohort of older adults with a mean age of 76.5 years, having an 
ACB score >1 was associated with falls (OR = 1.8 (1.1-3.0); P = 0.01) [3]. Nevertheless, Fraser 
and colleagues in a 10 year follow up observational study of older adults with a baseline mean 
age of 71.1 years, observed that when adjusting for potential confounders associated with an 
increased risk of falling such as diabetes, prostate cancer, osteoarthritis, and Parkinson’s 
disease, the association between anti-cholinergic medication use and falls was lost (OR = 1.17 
(0.97–1.41); P = 0.096) [20]. 
Although one study has already reported an association between anti-cholinergic 
medication use and a history of falls in post-menopausal women over the age of 65, our study 
focuses on a younger and relatively healthy cohort of post-menopausal women under 65 years 
[23]. We therefore extend the evidence base by examining whether such a link exists before 
older age, whilst being mindful that we cannot draw any conclusions about causality given the 
observational nature of our study design. Our data show that ACB is associated with higher 
odds for falling in a group of people previously thought not to be adversely affected to this 
extent by anti-cholinergic medications. The relatively high ACB threshold associated with a 
history of falls in our study likely relates to the younger age of our study participants. It has 
been demonstrated that anti-cholinergic drug use is associated with decreased functional reach 
in older people, which may result in the reduced ability to actively prevent falling [3].  
Both central and peripheral effects of anti-cholinergics may contribute to falls risk [24, 
25]. Centrally, anti-cholinergic medications antagonise post-synaptic M1 receptors found in 
the central nervous system, which may produce abnormalities in perception and attention [26]. 
Peripherally, anti-cholinergic medications block M3 receptors in the eyes with resultant 
inability of the pupils to appropriately accommodate to near objects [27].  The combination of 
perceptual and visual impairment may contribute to the falls risk.  
Whilst we did not find that ACB relates to fractures, there is overwhelming evidence to 
suggest that the risk of falling is higher in people that have fallen previously, and that a history 
of falling is the strongest risk factor for low trauma fractures in older people [28-30]. 
Additionally, fear of falling is associated with a loss of perception of one’s own capabilities, 
loss of self-confidence and avoidance of activities [31]. In a systematic review of 28 studies, it 
has been shown that the greatest risk factor for developing a fear of falling in people aged ≥65 
was having fallen at a younger age [31].  
Whilst the relationship between anti-cholinergic medication and BMD has been 
investigated previously, there are limited reports on the association between anti-cholinergic 
medication use and BMD at Ward’s triangle [20]. Ward’s triangle is a fracture prone site, due 
to it being the weakest point on the neck of femur, varying with the individuals’ neck of femur 
shape [32]. However, the literature on Ward’s triangle is conflicting primarily due to 
inconsistency in locating Ward’s triangle radiologically and on DXA scans [33]. Our study 
findings should be replicated using Ward’s triangle measured using modern software 
programmes, where anatomical location can be more accurately identified.  
A positive association between extensive use of anti-cholinergic medications and 
decreased femoral neck BMD has been reported previously although this association was not 
significant following covariate adjustment [20]. We found no association between ACB and 
the lowest quintile BMD of the total hip, neck of femur, trochanter and lumbar spine, in both 
the univariate and multivariate analyses.  
Our study benefits from a number of strengths. It was conducted in a well characterised 
representative cohort of Scottish middle aged women who were selected at random from 
Community Health Index records. Our focus is on a younger cohort of women with a similar 
range of functioning, which means that our findings more accurately reflect the effects of ACB 
in middle age. A detailed and up to date medication list was recorded by a radiographer during 
participants’ visit to the DXA scanner, thus strengthening the accuracy of documentation of 
medications.  We adjusted for a comprehensive range of co-morbidities and medications known 
to affect our measured outcomes.  
We acknowledge some limitations. Given that our study is a cross sectional analysis, 
we are unable to determine causality. Consequently, a high ACB score may in fact be a marker 
of ill health and therefore it may be the case that ill health itself is the actual precipitating factor 
in falls. Information on falls and fractures were self-reported, raising the possibility of recall 
bias. However, given that our cohort’s ages ranged between 50-63 years, their recall ability is 
likely to have been good overall especially for uncommon and memorable events such as 
falling in this age group. Our measurement of physical activity level lacked the sensitivity to 
differentiate between weight bearing activities such as high intensity resistance and impact 
training which are more closely associated with increased or maintained BMD than simply 
walking or performing routine daily activities, which was the focus of our measurement tool 
[34-36]. We did not have information on the duration of medication use nor temporal 
relationship between ACB and a history of falls, therefore we were unable to rule out the 
possibility of reverse causality with any degree of confidence.  Moreover, we did not have 
information on the dose nor duration of anti-cholinergic medications being used by 
participants, therefore we were unable to observe any potential dose dependent or temporal 
relationship between ACB and a history of falls. We also did not have detailed information of 
falls such as severity, and impact of the falls. Because there is low to moderate concordance 
between anti-cholinergic burden scales, it is unclear that ACB is the most appropriate scale to 
predict our measured outcomes.37 Future studies should compare the utility of different 
anticholinergic scales in predicting falls outcome 
Nevertheless, we have shown that high ACB scores are associated with a higher 
likelihood of having fallen in the last year. Per 100 population, we found that a history of 
falls in middle-aged women with a high ACB score was almost one third (32).  Additionally, 
we found the link between high ACB and low BMD at the Ward’s triangle. This finding 
warrants further investigation as this may provide potential mechanistic link between high 
ACB and falls observed in older age. Our findings suggest that the falls risk associated with 
ACB observed in older age may extend to middle age and high ACB may have potential 
clinical utility as a novel risk marker in identifying older women with high risk of falls and 
fractures for targeted intervention strategies.   
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Table 1: Participant characteristics of full cohort and by anti-cholinergic burden score in 
3883 middle-aged women of APOSS at second visit. 
 Full cohort  
n=3883 
ACB score 0 
n=3293 
ACB score 
1 
n=328 
ACB score 
≥2 
n=262 
P 
Characteristics      
 Age (years) 54.33 
(2.27) 
54.26 (2.24) 54.63 
(2.37) 
54.79 
(2.36) 
<0.001 
 BMI (kg/m2) 26.78 
(4.87) 
26.51(4.61) 28.08 
(5.36) 
28.52 
(6.55) 
<0.001 
 Physical activity 
(PAL) 
1.82 (0.32) 1.84 (0.32) 1.75 (0.31) 1.70 (0.34) <0.001 
Menopausal 
Status  
    0.006 
 Pre and peri-
menopausal 
377 (10) 341(10) 20 (6) 16 (6)  
 Post-menopausal 3496 (90) 2943 (89) 308 (94) 245 (94)  
Co-morbidities       
 Falls during past 
12 months 
855 (22) 703 (21) 69 (21) 83 (32) <0.001 
 Ever fractured a 
bone 
1183 (30) 998 (30) 111 (34) 74 (28) 0.30 
 Osteoporosis 31 (1) 25 (1) 3 (1) 3 (1) 0.77 
 Osteoarthritis 290 (7) 236 (7) 26 (8) 28 (11) 0.10 
 Rheumatoid 
arthritis 
54 (1) 36 (1) 10 (3) 8 (3) 0.001 
 Kidney disease 22 (1) 14 (1) 4 (1) 4 (2) 0.018 
 Diabetes 27 (1) 15 (0) 6 (2) 6 (2) <0.001 
 Hypertension 269 (6) 158 (5) 69 (21) 42 (16) <0.001 
 Asthma 145 (4) 109 (3) 15 (5) 21 (8) <0.001 
 Mother has broken 
their hip 
279 (7) 246 (7) 16 (5) 17 (6) 0.21 
 Thyroid disease 172 (4) 142 (4.3) 18 (5) 12 (5) 0.61 
 25OHD≤25 
nmol/L 
3113 (80.2) 1856 (56.4) 179 (54.6) 154 (58.8) 0.10 
Medication       
 Current HRT user 1080 (28) 911 (28) 87 (27) 82 (31) 0.39 
 Current smoker 733 (19) 615 (19) 66 (20) 52 (20) 0.75 
 Medication for 
osteoporosis 
19 (0) 13 (0) 3 (1) 3 (1) 0.13 
 Calcium 
supplements 
329 (8) 279 (8) 26 (8) 24 (9) 0.86 
 Steroid tablets 163 (4) 127 (4) 18 (5) 18 (7) 0.03 
 Oral contraceptive  1305 (34) 1122 (34) 110 (34) 73 (28) 0.13 
 Diuretics 339 (9) 229 73 37 <0.001 
 Anti-epileptics 19 (0) 13 (0) 1 (0) 5 (2) 0.003 
BMD (g/cm3)      
 Total Hip  2.28 (0.37) 1.54 (0.23) 1.56 (0.23) 1.55 (0.23) 0.09 
 Ward’s Triangle  0.74 (0.16) 0.74 (0.16) 0.75 (0.17) 0.73 (0.18) 0.36 
 Neck of Femur  0.84 (0.12) 0.84 (0.12) 0.85 (0.12) 0.84 (0.13) 0.19 
 Trochanter  0.70 (0.12) 0.70 (0.12) 0.72 (0.12) 0.70 (0.13) 0.08 
 Spine (L2 - L4)  1.01 (0.17) 1.01 (0.17) 1.03 (0.17) 1.03 (0.19) 0.01 
T-scores      
 Neck of Femur -0.84 (0.76) -0.84 (0.74) -0.81 
(0.78) 
-0.84 
(0.93) 
0.82 
 Spine (L2 - L4) -0.97 (1.48) -1.00 (1.47) -0.81 
(1.46) 
-0.76 
(1.66) 
0.005 
Z-scores      
 Neck of Femur -0.37 (0.83) -0.38 (0.84) -0.25 
(0.82) 
-0.33 
(0.76) 
0.13 
 Spine (L2 - L4) 0.29 (1.27) 0.27 (1.27) 0.46 (1.21) 0.45 (1.30) 0.08 
Values presented are mean (SD) for continuous data and number (%) for categorical data. 
P values were generated using a one-way ANOVA test for continuous variables and a chi 
square test for categorical variables. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Results of logistic regression analysis examining the association between anti-
cholinergic burden (reference category = 0) and a history of falls over the previous 12 months 
Models ACB 1  ACB ≥2 
  OR 95% CI P OR 95% CI P 
Falls in the last year         
A 0.95 0.72-1.27 0.72 1.71 1.30-2.25 <0.001 
B 0.91 0.69-1.21 0.52 1.63 1.24-2.16 0.001 
C 0.93 0.68-1.28 0.66 1.69 1.24-2.32 0.001 
D 1.06 0.74-1.51 0.75 1.84 1.28-2.64 0.001 
E 1.06 0.74-1.52 0.74 1.80 1.25-2.60 0.002 
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, fractured a bone since turning 50 years of age, kidney 
disease, thyroid disease, diabetes mellitus, current smoker, hypertension, stroke, mother has 
broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
 
 
 
 
 
 
 
 
 
Table 3: Results of logistic regression analyses examining association between anti-
cholinergic burden (reference category = 0) and hip and spine bone mineral density 
Models ACB 1 ACB ≥2 
 OR 95% CI P OR 95% CI P 
Lowest 20% of total hip 
BMD 
      
A 0.94 0.61-1.44 0.76 1.36 0.89-2.07 0.16 
B 1.11 0.71-1.75 0.64 1.45 0.92-2.30 0.11 
C 0.90 0.53-1.55 0.71 1.19 0.69-2.04 0.53 
D 0.97 0.53-1.79 0.92 1.18 0.64-2.20 0.60 
E 0.95 0.51-1.77 0.88 1.13 0.60-2.11 0.71 
Lowest 20% of Ward's 
triangle BMD 
    
A 1.52 0.75-3.08 0.25 3.07 1.66-5.66 <0.001 
B 1.70 0.82-3.51 0.15 2.81 1.46-5.43  0.002 
C 1.50 0.62-3.59 0.37 2.77 1.29-5.94  0.009 
D 1.87 0.70-4.95 0.21 2.86 1.19-6.88  0.019 
E 1.82 0.68-4.85 0.23 2.81 1.16-6.79  0.022 
Lowest 20% of neck of 
femur BMD 
      
A 0.79 0.34-1.83 0.58 1.40 0.67-2.94 0.37 
B 0.96 0.41-2.23 0.92 1.13 0.48-2.67 0.78 
C 0.59 0.18-1.92 0.38 0.91 0.32-2.57 0.85 
D 0.82 0.25-2.72 0.75 0.80 0.24-2.70 0.72 
E 0.79 0.24-2.62 0.70 0.79 0.23-2.69 0.71 
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, kidney disease, thyroid disease, diabetes mellitus, current 
smoker, hypertension, stroke, fallen in the last year, fractured a bone since turning 50 years of 
age, mother has broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
 
 
 
 
 
 
 
Lowest 20% of 
trochanter BMD 
      
A 0.73 0.54-1.17 0.24 1.05 0.71-1.56 0.81 
B 0.96 0.64-1.45 0.86 1.24 0.81-1.89 0.32 
C 0.88 0.55-1.42 0.61 1.21 0.75-1.95 0.43 
D 0.95 0.55-1.62 0.84 1.32 0.78-2.27 0.30 
E 0.96 0.56-1.66 0.89 1.28 0.74-2.20 0.38 
Lowest 20% of spine 
BMD 
      
A 0.75 0.54-1.04 0.08 0.99 0.71-1.38 0.95 
B 1.13 0.59-1.16 0.27 1.07 0.75-1.52 0.71 
C 0.76 0.51-1.13 0.17 0.99 0.66-1.49 0.96 
D 0.72 0.45-1.15 0.17    1.03 0.65-1.64 0.90 
E 0.72 0.45-1.16 0.18 1.08 0.67-1.73 0.76 
Supplementary Table 1: Anti-cholinergic burden scoring table. 
Medications 
ACB score of 1        ACB score of 2 ACB score of 3 
 Alimemazine  
Alprazolam  
Alverine  
Aripiprazole  
Asenapine  
Atenolol  
Bupropion  
Captopril  
Cetirizine  
Chlorthalidone  
Cimetidine  
Clidinium  
Clorazepate  
Codeine  
Colchicine  
Desloratadine  
Diazepam  
Digoxin  
Dipyridamole  
Fentanyl  
Fluvoxamine  
Furosemide  
Haloperidol  
Hydralazine  
Hydrocortisone  
Iloperidone  
Isosorbide  
Levocetirizine  
Amantadine  
Belladonna  
Carbamazepine  
Cyclobenzaprine 
Cyproheptadine  
Loxapine  
Meperidine  
Methotrimeprazine  
Molindone  
Nefopam  
Oxcarbazepine  
Pimozide  
Amitriptyline 
Amoxapine 
Atropine 
Benztropine 
Brompheniramine 
Carbinoxamine 
Chlorpheniramine 
Chlorpromazine 
Clemastine 
Clomipramine 
Clozapine 
Darifenacin 
Desipramine 
Dicyclomine 
Dimenhydrinate 
Diphenhydramine 
Doxepin 
Doxylamine 
Fesoterodine 
Flavoxate 
Hydroxyzine 
Hyoscyamine 
Imipramine 
Meclizine 
Methocarbamol 
Nortriptyline 
Olanzapine 
Orphenadrine 
Loperamide  
Loratadine  
Metoprolol  
Morphine  
Nifedipine  
Paliperidone  
Prednisone  
Quinidine  
Ranitidine  
Risperidone  
Theophylline  
Trazodone  
Triamterene  
Venlafaxine  
Warfarin  
Oxybutynin 
Paroxetine 
Perphenazine 
Promethazine 
Propantheline 
Propiverine 
Quetiapine 
Scopolamine 
Solifenacin 
Thioridazine 
Tolterodine 
Trifluoperazine 
Trihexyphenidyl 
Trimipramine 
Trospium 
 
ACB score of 1 = Evidence from in vitro data that chemical entity has antagonist activity at 
muscarinic receptor. 
ACB score of 2 = Evidence from literature, prescriber’s information, or expert opinion of 
clinical anti-cholinergic effect. 
ACB score of 3 = Evidence from literature, expert opinion, or prescribers’ information that 
medication may cause delirium. 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Results of logistic regression analysis examining the association 
between anti-cholinergic burden (reference category = 0) and a history of falls over the 
previous 12 months. 
Models ACB ≥1 
  OR 95% CI P 
Falls in the last year     
A 1.29 1.05-1.58 0.014 
B 1.23 1.00-1.51 0.05 
C 1.27 1.00-1.60 0.048 
D 1.42 1.09-1.86 0.010 
E 1.41 1.08-1.85 0.013 
 
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, fractured a bone since turning 50 years of age, kidney 
disease, thyroid disease, diabetes mellitus, current smoker, hypertension, stroke, mother has 
broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
 
 
 
 
 
 
 
 
Supplementary Table 3: Results of logistic regression analyses examining association 
between anti-cholinergic burden (reference category = 0) and hip and spine bone mineral 
density. 
Models ACB ≥1 
 OR 95% CI P 
Lowest 20% of total hip 
BMD 
  
A 1.13 0.82-1.55 0.46 
B 1.30 0.92-1.80 0.14 
C 1.04 0.70-1.54 0.85 
D 1.07 0.68-1.69 0.77 
E 1.04 0.66-1.64 0.88 
Lowest 20% of Ward's 
triangle BMD 
 
A 2.42 1.46-4.02 0.001 
B 2.44 1.44-4.15 0.001 
C 2.27 1.22-4.23 0.009 
D 2.62 1.29-5.34 0.008 
E 2.56 1.25-5.23 0.010 
Lowest 20% of neck of 
femur BMD 
   
A 1.06 0.60-1.90 0.84 
B 1.04 0.56-1.95 0.90 
C 0.73 0.33-1.62 0.43 
D 0.80 0.33-1.93 0.62 
E 0.78 0.32-1.88 0.58 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, kidney disease, thyroid disease, diabetes mellitus, current 
smoker, hypertension, stroke, fallen in the last year, fractured a bone since turning 50 years of 
age, mother has broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
 
 
 
 
 
Lowest 20% of 
trochanter BMD 
   
A 0.90 0.67-1.20 0.46 
B 1.09 0.80-1.48 0.58 
C 1.03 0.73-1.46 0.86 
D 1.12 0.76-1.67 0.57 
E 1.11 0.75-1.66 0.60 
Lowest 20% of spine 
BMD 
   
A 0.84 0.66-1.07 0.16 
B 0.93 0.72-1.19 0.55 
C 0.86 0.65-1.16 0.32 
D 0.84 0.60-1.18 0.32 
E 0.86 0.61-1.22 0.40 
Supplementary Table 4: Results of multiple linear regression analyses examining association 
between anti-cholinergic burden (reference category = 0) and hip and spine bone mineral 
density (N =3883).  
Models ACB 1 ACB ≥2 
 B SE P B SE P 
Total hip BMD       
A 0.03 0.02 0.11 <0.01 0.02 0.87 
B 0.01 0.02 0.78 -0.04 0.02 0.12 
C 0.01 0.02 0.78 -0.03 0.03 0.31 
D 0.01 0.03 0.63 -0.04 0.03 0.20 
E 0.01 0.03 0.57 -0.03 0.03 0.37 
Ward's triangle BMD     
A 0.01 0.01 0.32 -0.01 0.01 0.26 
B <0.01 0.01 0.80 -0.02 0.01 0.042 
C <0.01 0.01 0.87 -0.02 0.01 0.14 
D <0.01 0.01 0.99 -0.02         0.01 0.07 
E <0.01 0.01 0.93 -0.02 0.01 0.23 
Neck of femur BMD       
A 0.01 0.01 0.14 0.01 0.01 0.33 
B <0.01 0.01 0.83 <0.01 0.01 0.94 
C <0.01 0.01 0.70 <0.01 0.01 0.85 
D 0.01 0.01 0.46 <0.01 0.01 0.80 
E 0.01 0.01 0.43 <0.01 0.01 0.76 
Trochanter BMD       
A 0.02 0.01 0.027 <0.01 0.01 0.60 
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, kidney disease, thyroid disease, diabetes mellitus, current 
smoker, hypertension, stroke, fallen in the last year, fractured a bone since turning 50 years of 
age, mother has broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
 
 
 
 
 
 
 
 
 
B <0.01 0.01 0.78 -0.01 0.01 0.049 
C <0.01 0.01 0.81 -0.01 0.001 0.19 
D 0.01 0.01 0.47 -0.02 0.01 0.08 
E 0.01 0.01 0.41 -0.01 0.001 0.13 
Spine BMD       
A 0.02 0.01 0.06 0.02 0.01 0.031 
B 0.01 0.01 0.44 0.01 0.01 0.39 
C 0.01 0.01 0.58 0.02 0.01 0.22 
D 0.01 0.01 0.51 0.01 0.01 0.33 
E 0.01 0.01 0.52 0.01 0.01 0.35 
Supplementary Table 5: Results of multiple linear regression analyses examining association 
between anti-cholinergic burden (reference category = 0) and T-scores of lumbar spine and 
neck of femur (N =3870).  
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, kidney disease, thyroid disease, diabetes mellitus, current 
smoker, hypertension, stroke, fallen in the last year, fractured a bone since turning 50 years of 
age, mother has broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
 
 
 
 
Models ACB 1 ACB ≥2 
 B SE P B SE P 
T-score of lumbar spine       
A 0.17 0.09 0.044 0.22 0.10 0.019 
B 0.07 0.08 0.37 0.10 0.09 0.28 
C 0.06 0.09 0.49 0.15 0.10 0.15 
D 0.08 0.11 0.45 0.14 0.12 0.23 
E 0.08 0.11 0.45 0.14 0.12 0.25 
T-score neck of femur     
A 0.03 0.04 0.53 <-0.01 0.05 0.98 
B -0.01 0.04 0.78 -0.04 0.05 0.41 
C -0.01 0.05 0.77 -0.01 0.05 0.87 
D -0.02 0.05 0.77 -0.05       0.06 0.43 
E -0.01 0.05 0.85 -0.03 0.06 0.66 
Supplementary Table 6: Results of multiple linear regression analyses examining association 
between anti-cholinergic burden (reference category = 0) and Z-scores of lumbar spine and 
neck of femur (N =1864).  
Model A: Unadjusted. 
Model B: Adjusted for age, BMI and current hormone replacement therapy. 
Model C: Model B additionally adjusted for menopausal status and physical activity level. 
Model D: Model C additionally adjusted for history of comorbidities: osteoporosis, 
osteoarthritis, rheumatoid arthritis, kidney disease, thyroid disease, diabetes mellitus, current 
smoker, hypertension, stroke, fallen in the last year, fractured a bone since turning 50 years of 
age, mother has broken their hip, 25OHD ≤25 nmol/L. 
Model E: Model D additionally adjusted for other medications taken; corticosteroids, oral 
contraceptive, calcium supplements, osteoporosis medication, anti-epileptic medication, 
diuretics. 
 
Models ACB 1 ACB ≥2 
 B SE P B SE P 
Z-score of lumbar spine       
A 0.18 0.11 0.09 0.16 0.13 0.19 
B 0.10 0.10 0.33 <0.01 0.12 0.98 
C 0.08 0.12 0.50 0.06 0.13 0.68 
D 0.10 0.14 0.46 0.07 0.16 0.66 
E 0.09 0.14 0.53 0.09 0.17 0.59 
Z-score neck of femur     
A 0.13 0.07 0.06 0.05 0.08 0.57 
B 0.06 0.07 0.37 -0.05 0.08 0.53 
C 0.08 0.07 0.29 -0.06 0.09 0.49 
D 0.12 0.09 0.17 -0.01         0.10 0.94 
E 0.12 0.09 0.17 0.02 0.11 0.86 
